HC Wainwright reissued their buy rating on shares of ObsEva SA (NASDAQ:OBSV) in a report published on Wednesday. They currently have a $25.00 price objective on the stock.

Several other equities analysts also recently commented on OBSV. Zacks Investment Research upgraded ObsEva SA from a sell rating to a hold rating in a research report on Wednesday, July 19th. Leerink Swann restated an outperform rating and issued a $18.00 price objective on shares of ObsEva SA in a research report on Wednesday, August 16th. Royal Bank Of Canada initiated coverage on ObsEva SA in a research report on Thursday, September 14th. They issued an outperform rating and a $22.00 price objective on the stock. Finally, Credit Suisse Group started coverage on ObsEva SA in a research report on Monday, October 9th. They issued an outperform rating and a $16.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average target price of $18.83.

ObsEva SA (OBSV) traded up $0.69 during trading hours on Wednesday, reaching $11.50. The company’s stock had a trading volume of 10,501 shares, compared to its average volume of 46,356. ObsEva SA has a twelve month low of $5.00 and a twelve month high of $14.69.

ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter last year, the company earned ($0.30) earnings per share. equities research analysts expect that ObsEva SA will post -2.37 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/obseva-sas-obsv-buy-rating-reaffirmed-at-hc-wainwright/1691641.html.

A number of hedge funds have recently modified their holdings of the business. Paloma Partners Management Co purchased a new stake in ObsEva SA during the first quarter valued at approximately $131,000. Sphera Funds Management LTD. raised its position in ObsEva SA by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after purchasing an additional 20,411 shares during the period. Sectoral Asset Management Inc raised its position in ObsEva SA by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after purchasing an additional 137,331 shares during the period. Finally, VHCP Management II LLC purchased a new stake in ObsEva SA during the second quarter valued at approximately $1,283,000. Institutional investors and hedge funds own 48.46% of the company’s stock.

ObsEva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

Analyst Recommendations for ObsEva SA (NASDAQ:OBSV)

Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with Analyst Ratings Network's FREE daily email newsletter.